Program
Day 1, September 15, 2021 | |
---|---|
14.00–14.45 CET Keynote lecture |
Evolution and future of oncohematology testing Prof. Dr. Martin C. Müller, CEO, Institute for Hematology and Oncology, Germany |
14.45–15.30 CET |
Improved leukemia patient care with molecular detection and quantification Anna Tarasewicz, Haematology & Blood Transfusion BSUH and Munyoro Guvamatanga, Princess Elizabeth Hospital Guernsey, UK |
15.30–15.45 CET |
Break |
15.45–16.30 CET |
Implementation of a comprehensive genomic profiling approach for myeloid neoplasms Dr. Vincent Funari, NeoGenomics, USA |
16.30–17.15 CET |
Reality and challenges of oncohematology testing Dr. Susanna Akiki, Hamad Medical Corporation, Qatar |
Day 2, September 16, 2021 | |
---|---|
15.00–15.45 CET Presentation |
The new EU IVD Regulation Volker Franzen, Senior Director Regulatory and Governmental Affairs, QIAGEN, Germany |
15.45–16.30 CET |
Overcoming challenges of NGS panel workflows for myeloid neoplasms applications Krishna Amin, Global Product Manager Targeted Genomics, QIAGEN, USA |
16.30–16.45 CET |
Break |
16.45–17.45 CET |
Evolution and future of oncohematology testing Dr. Susanna Akiki (Qatar), Prof. Dr. Susan Branford (Australia), Prof. Dr. Ross Levine (USA) and Prof. Dr. Martin C. Müller (Germany); Moderator: Davide Manissero, Chief Medical Officer, QIAGEN, UK |
Speakers
Registration
Need some help?
Contact our events team with any questions about the Oncohematology Summit